Last Updated: 15/07/2022
VivAccess: A Market Manager for Optimizing Plasmodium vivax Radical Cure
Objectives
To facilitate access to Plasmodium vivax safe radical-cure product packages, including new products, in priority countries.
Specific Objectives
- Coordinate global strategy for introduction and scale of vivax products.
- Package of P. vivax diagnostics and drugs registered, procured, and available in 15 priority countries, including primaquine, tafenoquine, quantitative G6PD diagnostics, and improved P. vivax diagnostics.
Principal Institution
PATH, United States
Medicines for Malaria Venture (MMV), Switzerland
Principal Investigators / Focal Persons
Project Outputs
National Pharmacovigilance (PV) System in Myanmar: A reviewSmall changes, big savingsG6PD deficiency in Myanmar: A brief on available evidenceCompliance and Adherence to Primaquine Treatment in MyanmarMarkets for Malaria: Improving Access to Medicines and Diagnostics
External reference